✦ LIBER ✦

Paclitaxel vs Epidoxorubicin plus Paclitaxel as Second-Line Therapy for Platinum-Refractory and -Resistant Ovarian Cancer

✍ Scribed by Giorgio Bolis; Fabio Parazzini; Giovanna Scarfone; Antonella Villa; Mariangela Amoroso; Emanuela Rabaiotti; Anna Polatti; Simona Reina; Elena Pirletti

Book ID: 112247573
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 46 KB
Volume: 72
Category: Article
ISSN: 0090-8258
DOI: 10.1006/gyno.1998.5237

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Carboplatin Alone vs Carboplatin plus Ep

Carboplatin Alone vs Carboplatin plus Epidoxorubicin as Second-Line Therapy for Cisplatin- or Carboplatin-Sensitive Ovarian Cancer

✍ Giorgio Bolis; Giovanna Scarfone; Giorgio Giardina; Antonella Villa; Giorgia Man 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 73 KB

Paclitaxel Carboplatin chemotherapy as a

Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases

✍ Norihito Soga; Takehisa Onishi; Kiminobu Arima; Yoshiki Sugimura 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

A phase I study of paclitaxel and altret

A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer

✍ Ian Olver; Margaret Davy; Diana Lüftner; So-Hyang Park; Merrill Egorin; Andrew E 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 96 KB

Docetaxel-based chemotherapy as second-l

Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: A pilot study

✍ Shinji Urakami; Tateki Yoshino; Nobuyuki Kikuno; Shin Imai; Satoshi Honda; Tatua 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 107 KB

A phase II trial of weekly 1-hour paclit

A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer

✍ Howard D. Homesley; Nathan P. Meltzer; Lucybeth Nieves; Luis Vaccarello; George 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 199 KB

Gemcitabine and docetaxel as second-line

Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens

✍ Christos Kosmas; Nicolas Tsavaris; Maria Vadiaka; Niki Stavroyianni; Angelos Kou 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 2 views